vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $23.0M, roughly 1.1× Intellia Therapeutics, Inc.). First Bancorp, Inc runs the higher net margin — 39.4% vs -416.2%, a 455.5% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 17.5%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-69.4M). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs -10.8%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FNLC vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $23.0M |
| Net Profit | $10.2M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 48.1% | -428.9% |
| Net Margin | 39.4% | -416.2% |
| Revenue YoY | 17.5% | 78.8% |
| Net Profit YoY | 39.7% | 25.7% |
| EPS (diluted) | $0.91 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $23.0M | ||
| Q3 25 | $24.5M | $13.8M | ||
| Q2 25 | $22.5M | $14.2M | ||
| Q1 25 | $21.8M | $16.6M | ||
| Q4 24 | $22.0M | $12.9M | ||
| Q3 24 | $20.5M | $9.1M | ||
| Q2 24 | $19.2M | $7.0M | ||
| Q1 24 | $18.5M | $28.9M |
| Q4 25 | $10.2M | $-95.8M | ||
| Q3 25 | $9.1M | $-101.3M | ||
| Q2 25 | $8.1M | $-101.3M | ||
| Q1 25 | $7.1M | $-114.3M | ||
| Q4 24 | $7.3M | $-128.9M | ||
| Q3 24 | $7.6M | $-135.7M | ||
| Q2 24 | $6.2M | $-147.0M | ||
| Q1 24 | $6.0M | $-107.4M |
| Q4 25 | 48.1% | -428.9% | ||
| Q3 25 | 45.2% | -808.9% | ||
| Q2 25 | 43.7% | -772.2% | ||
| Q1 25 | 39.3% | -726.6% | ||
| Q4 24 | 39.5% | -1059.9% | ||
| Q3 24 | 44.6% | -1589.0% | ||
| Q2 24 | 38.8% | -1998.6% | ||
| Q1 24 | 39.3% | -394.0% |
| Q4 25 | 39.4% | -416.2% | ||
| Q3 25 | 37.0% | -735.2% | ||
| Q2 25 | 35.8% | -710.8% | ||
| Q1 25 | 32.5% | -687.6% | ||
| Q4 24 | 33.1% | -1001.2% | ||
| Q3 24 | 36.9% | -1489.5% | ||
| Q2 24 | 32.1% | -2112.6% | ||
| Q1 24 | 32.5% | -371.3% |
| Q4 25 | $0.91 | $-0.81 | ||
| Q3 25 | $0.81 | $-0.92 | ||
| Q2 25 | $0.72 | $-0.98 | ||
| Q1 25 | $0.63 | $-1.10 | ||
| Q4 24 | $0.66 | $-1.27 | ||
| Q3 24 | $0.68 | $-1.34 | ||
| Q2 24 | $0.55 | $-1.52 | ||
| Q1 24 | $0.54 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | $95.5M | — |
| Stockholders' EquityBook value | $283.1M | $671.4M |
| Total Assets | $3.2B | $842.1M |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $95.5M | — | ||
| Q3 25 | $95.5M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | $95.0M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.0M | — | ||
| Q1 24 | $70.0M | — |
| Q4 25 | $283.1M | $671.4M | ||
| Q3 25 | $274.6M | $748.4M | ||
| Q2 25 | $265.5M | $715.3M | ||
| Q1 25 | $259.7M | $779.9M | ||
| Q4 24 | $252.5M | $872.0M | ||
| Q3 24 | $256.8M | $962.6M | ||
| Q2 24 | $244.7M | $971.1M | ||
| Q1 24 | $242.6M | $1.0B |
| Q4 25 | $3.2B | $842.1M | ||
| Q3 25 | $3.2B | $925.3M | ||
| Q2 25 | $3.2B | $898.9M | ||
| Q1 25 | $3.2B | $986.2M | ||
| Q4 24 | $3.2B | $1.2B | ||
| Q3 24 | $3.1B | $1.2B | ||
| Q2 24 | $3.1B | $1.2B | ||
| Q1 24 | $3.0B | $1.3B |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $-69.3M |
| Free Cash FlowOCF − Capex | $34.6M | $-69.4M |
| FCF MarginFCF / Revenue | 133.9% | -301.6% |
| Capex IntensityCapex / Revenue | 12.5% | 0.5% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $-69.3M | ||
| Q3 25 | $12.9M | $-76.9M | ||
| Q2 25 | $7.4M | $-99.6M | ||
| Q1 25 | $2.2M | $-148.9M | ||
| Q4 24 | $26.0M | $-85.2M | ||
| Q3 24 | $9.8M | $-84.8M | ||
| Q2 24 | $6.4M | $-58.2M | ||
| Q1 24 | $-1.5M | $-120.7M |
| Q4 25 | $34.6M | $-69.4M | ||
| Q3 25 | $12.6M | $-76.9M | ||
| Q2 25 | $7.2M | $-99.9M | ||
| Q1 25 | $828.0K | $-149.7M | ||
| Q4 24 | $24.6M | $-86.2M | ||
| Q3 24 | $9.6M | $-86.1M | ||
| Q2 24 | $6.3M | $-59.2M | ||
| Q1 24 | $-1.8M | $-123.2M |
| Q4 25 | 133.9% | -301.6% | ||
| Q3 25 | 51.4% | -558.2% | ||
| Q2 25 | 32.1% | -701.0% | ||
| Q1 25 | 3.8% | -900.1% | ||
| Q4 24 | 111.7% | -669.4% | ||
| Q3 24 | 47.0% | -945.2% | ||
| Q2 24 | 32.9% | -850.9% | ||
| Q1 24 | -9.8% | -425.7% |
| Q4 25 | 12.5% | 0.5% | ||
| Q3 25 | 1.2% | 0.2% | ||
| Q2 25 | 0.6% | 1.7% | ||
| Q1 25 | 6.2% | 4.4% | ||
| Q4 24 | 6.7% | 7.6% | ||
| Q3 24 | 0.5% | 14.0% | ||
| Q2 24 | 0.3% | 14.5% | ||
| Q1 24 | 1.8% | 8.7% |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
